Sarcopenia and Frailty in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Impact of Steroid Hormones
Authors:
- Triada BaliTBTriada Bali
- Jennifer LaiJLJennifer Lai
- Niki G. MourelatouNMNiki G. Mourelatou
- Aristi SaridakiASAristi Saridaki
- Sofia TsitsouSTSofia Tsitsou
- Magdalini AdamantouMAMagdalini Adamantou
- Aikaterini KamiliouAKAikaterini Kamiliou
- Christos ChologitasCCChristos Chologitas
- Margarita SarriMSMargarita Sarri
- Dimitra PavlopoulouDPDimitra Pavlopoulou
- Evangelos LiberopoulosEvangelos Liberopoulos
- Anna AngelousiAAAnna Angelousi
Open Access
- 20 August 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7431
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to sarcopenia and frailty, but data on white populations remain limited. This study evaluated sarcopenia, physical performance and steroid hormone associations with frailty in European MASLD patients. A cross-sectional study included 245 white MASLD patients. Clinical, biochemical, hormonal and elastography data were collected. Sarcopenia was assessed using dual-energy X-ray absorptiometry alongside mid-arm muscle circumference (MAMC), while physical performance was assessed using the liver frailty index (LFI) and the short physical performance battery (SPPB). Mean age was 56.2 years, 45.7% were male, and median liver stiffness was 5.2 kPa; 76.3% and 33.9% of patients had low MAMC and Appendicular Lean Mass Index, while 13.5% had abnormal SPPB and 16% were frail (i.e., LFI > 4.4). Poor physical performance was linked to lower dehydroepiandrosterone sulfate (DHEAS) levels using both LFI (OR: 0.98, 95% C.I.: 0.96–0.99, p = 0.01) and SPPB (OR: 1.14, 95% C.I.: 1.003–1.22, p = 0.026). Frailty assessed by LFI was associated with increased liver stiffness (OR: 1.24, 95% C.I.: 1.047–1.482, p = 0.013). We concurrently evaluated muscle mass and frailty for the first time in a white MASLD cohort. Lower DHEAS levels were associated with impaired physical performance. Further studies are needed to confirm these findings and their possible therapeutic implications.Keywords
This publication has 46 references indexed in Scilit:
- SARCOPENIA IS A KEY DETERMINANT MARKER OF LEAN MASLD: A COMPARATIVE ANALYSIS OF CLINICAL PROFILE, BODY COMPOSITION BY DEXA, AND MUSCLE STRENGTH IN LEAN, OVERWEIGHT, AND OBESE MASLD PATIENTSAnnals of Hepatology, 2025
- The relationship between nonalcoholic fatty liver disease and frailty: A systematic review and meta-analysisDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2025
- Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysisAnnals of Hepatology, 2024
- Metabolic-Associated Fatty Liver Disease and SarcopeniaEndocrinology and Metabolism Clinics of North America, 2023
- Serum levels of dehydroepiandrosterone sulfate are associated with a lower risk of mobility-subtype frailty in older Japanese community-dwellersArchives of Gerontology and Geriatrics, 2022
- Sarcopenia: imaging assessment and clinical applicationAbdominal Radiology, 2021
- Frailty is associated with increased risk of cirrhosis disease progression and deathHepatology, 2021
- Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2021
- Low Testosterone Is Associated With Nonalcoholic Steatohepatitis and Fibrosis Severity in MenClinical Gastroenterology and Hepatology, 2021
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985